WSCM
MRNA icon

Wellington Shields Capital Management’s Moderna MRNA Stock Holding History

Wellington Shields Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,602
Closed -$107K – 319
2024
Q3 		$107K Hold
1,602
– – 0.02% 268
2024
Q2 		$190K Hold
1,602
– – 0.03% 235
2024
Q1 		$171K Buy
1,602
+1,600
+80,000% +$161K 0.03% 241
2023
Q4 		$199 Sell
2
-260
-99% -$21.9K ﹤0.01% 298
2023
Q3 		$27.1K Buy
262
+260
+13,000% +$29K ﹤0.01% 286
2023
Q2 		$243 Hold
2
– – ﹤0.01% 312
2023
Q1 		$307 Hold
2
– – ﹤0.01% 320
2022
Q4 		$359 Hold
2
– – ﹤0.01% 312
2022
Q3 		$0 Hold
2
– – ﹤0.01% 309
2022
Q2 		$0 Hold
2
– – ﹤0.01% 314
2022
Q1 		$0 Buy
+2
New +$337 ﹤0.01% 342

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Wellington Shields Capital Management's MRNA Position: Q4 2024 in Review

Wellington Shields Capital Management sold out of Moderna (MRNA) in Q4 2024, closing a stake of 1,602 shares — an estimated $107K sold.

Wellington Shields Capital Management first reported a position in MRNA in Q1 2022 and held it in 11 quarters. The position peaked at $190K in Q2 2024. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Wellington Shields Capital Management reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Wellington Shields Capital Management sold 1,602 Moderna shares in Q4 2024, an estimated $107K.
  • Wellington Shields Capital Management first reported a position in Moderna in Q1 2022 and held it in 11 quarters.
  • Wellington Shields Capital Management's Moderna position peaked at $190K in Q2 2024.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Wellington Shields Capital Management's 13F filing for Q4 2024, filed 10 Feb 2025.